Cipla Ltd

Large Cap

Healthcare Sector

reflects a positive outlook for the share price

reflects a neutral outlook for the share price

reflects a negative outlook for the share price

The analysts information is for reference only and does not\n  represents an investment recommendation.

Analyst recommendation reflect the views of analysts who follow and write research reports.

Company Information is an introduction to the company’s business that details what it sell, how it was founded, what their mission is, how they manufacture or source their products, and why they serve customers.

Cipla Limited announced its acquisition of a 100% stake in Inzpera Healthsciences for approximately ₹110.65 crore, enhancing its pediatric product portfolio and distribution capabilities.

Cipla Acquires 100% Stake in Inzpera Healthsciences - 03 Nov, 2025

Cipla's Q2 FY26 results show a 3.7% net profit increase and record revenue, but management changes and rising R&D costs lead to mixed brokerage ratings and a revised margin outlook.

Cipla Reports Q2 Growth Amid Management Changes - 31 Oct, 2025

Cipla's stock fell over 4% following Q2 results and CEO Umang Vohra's planned departure. Achin Gupta will succeed him in 2026. The company reported record revenue.

Cipla Announces Leadership Changes and Strong Q2 Results - 30 Oct, 2025

Cipla is projected to report stable Q2 FY26 results with a PAT of ₹1,361.6 crore, supported by domestic growth, despite US market pressures and pricing challenges.

Cipla Q2 FY26 Preview Shows Mixed Performance - 29 Oct, 2025

Cipla has entered a marketing agreement with Eli Lilly to launch Yurpeak for diabetes and obesity. Despite this, shares fell over 3% due to profit booking.

Cipla Launches Yurpeak Amidst Stock Fluctuations - 24 Oct, 2025

Cipla has secured distribution rights for Eli Lilly's tirzepatide, branded as Yurpeak, in India. This partnership aims to improve access to diabetes and weight-loss treatment nationwide.

Cipla Partners with Eli Lilly for Tirzepatide - 23 Oct, 2025

Cipla shares rallied 4% to a 52-week high of ₹1,640.65. Analysts predict further upside, targeting ₹1,770-₹1,850, supported by strong technical indicators and upcoming Q2 results.

Cipla Hits 52-Week High with Positive Outlook - 20 Oct, 2025

Cipla, in collaboration with Eli Lilly, completed a Phase 4 study on Lyumjev for Type 2 diabetes, potentially boosting market confidence. The stock shows upward momentum, targeting Rs 1770 to Rs 1850.

Cipla Advances in Diabetes Management and Stock Strength - 16 Oct, 2025

Choice Equity Broking advises buying Cipla shares in the ₹1,545-₹1,500 range, targeting ₹1,770 and ₹1,850, with support at ₹1,410.

Brokerage Recommends Accumulating Cipla Stock - 14 Oct, 2025

Cipla's stock performance is bolstered by reports of tariff exemptions on generics and its significant role in US prescriptions across major therapeutic areas.

Cipla Stock Gains Amid Positive Market News - 09 Oct, 2025

Price to Earnings Ratio or Price to Earnings Multiple is the ratio of the share price of a stock to its earnings per share (EPS). It provides an indication of whether a stock at its current market price is expensive or cheap.

The price/earnings-to-growth ratio, or the PEG ratio, is a metric that helps investors value a stock by taking into account a company's market price, its earnings, and its future growth prospects.

Enterprise value (EV) is the total value of a company, defined in terms of its financing. It includes both the current share price (market capitalization) and the cost to pay off debt (net debt, or debt minus cash).

Alpha measures the amount that the investment has returned in comparison to the market index or other broad benchmark that it is compared against.

Beta measures a stock's volatility, the degree to which its price fluctuates in relation to the overall stock market. In other words, it gives a sense of the stock's risk compared to that of the greater market.

Dividend yield measures the quantum of earnings by way of total dividends that investors make by investing in that company.

The debt-to-total-assets ratio shows how much of a business is owned by creditors (people it has borrowed money from) compared with how much of the company's assets are owned by shareholders.

Operating cash flow (OCF) is a measure of the amount of cash generated by a company's normal business operations. Operating cash flow indicates whether a company can generate sufficient positive cash flow to maintain and grow its operations.

This widget shows the information about the stock's peers in consideration along with the different data for those peers so that the user can compare the stock with the other similar stock and invest accordingly.

Promoter holding is the amount of share of the company that is owned by the promoters. The promoters are the company's founders, who hold a majority stake in the company's capital.

A foreign institutional investor (FII) is an investor or investment fund investing in a country outside of the one in which it is registered or headquartered.

A mutual fund is a pool of money managed by a professional Fund Manager. It is a trust that collects money from a number of investors who share a common investment objective and invests the same in equities, bonds, money market instruments, and other securities.

Retail investors execute their trades through traditional or online brokerage firms or other types of investment accounts. Retail investors purchase securities for their own personal accounts and often trade in dramatically smaller amounts as compared to institutional investors.

This widget shows the bifurcation of stocks based on the percentage of stake with the different types of shareholders.

This widget will help value the stock based on the Price to Earning ratio of the stock and compare the valuation with the industry value and other similar stocks. It even shows the timeline of the valuation of the stock and its highest and lowest valuation over time.
A Time Series data is provided which compares the historical stock PE with Industry PE over the period of 5 years.

Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.

Revenue is up for the last 3 quarters, 7.01K Cr → 7.85K Cr (in ₹), with an average increase of 5.5% per quarter

This section gives you an insight into how the revenue of the company has moved for the last few quarters.

Revenue Rich

Netprofit is up for the last 3 quarters, 1.22K Cr → 1.35K Cr (in ₹), with an average increase of 4.9% per quarter

This section gives you an insight into how the profit for the company has been for the last few quarters.

Profit Spike

Promoters holdings remained unchanged at 29.13% of holdings in Sep 2025 quarter

This section gives you an insight into how the Promoter Holding has changed for the stock over the last few quarters.

Promoter Holding Unchanged

In the last 3 years, Torrent Pharmaceuticals Ltd has given 117.7% return, outperforming this stock by 85.8%

This section gives you an insight into how the peers have performed as compared to this company in the last 3 years.

Against Peers

In the last 1 year, Divis Laboratories Ltd has given 15.3% return, outperforming this stock by 19.9%

This section gives you an insight into how the peers have performed as compared to this company in the last 1 year.

In the last 7 days, CIPLA stock has moved down by -3.6%

This section gives you an insight into the price movement of the stock for the last few quarters.

Price Dip

Mutual Funds have decreased holdings from 20.40% to 20.17% in Sep 2025 quarter

This section gives you an insight into how the Mutual Funds Holding has changed for the stock over last few quarters.

MF Holding Down

Foreign Institutions have decreased holdings from 25.19% to 24.47% in Sep 2025 quarter

This section gives you an insight into how the FII Holding has changed for the stock over last few quarters.

FII Holding Down

Retail Investor have decreased holdings from 16.27% to 15.94% in Sep 2025 quarter

This section gives you an insight into how the Retail Investors Holding has changed for the stock over last few quarters.

Retail Holding Down

Nifty100 Eq Weig

Nifty50 Value 20

NIFTY PHARMA

S&P BSE SENSEX 50

S&P BSE Largecap

BSE 100

Nifty Healthcare

NIFTY 100

S&P BSE 100 ESG

NIFTY 50

S&P BSE 100 LargeCap TMC

Nifty 200

S&P BSE 250 LargeMidCap

S&P BSE Dividend Stability

BSE 200

Nifty100 Low Volatility 30

Nifty 500

BSE Healthcare

Nifty LargeMidcap 250

BSE 500

BSE MFG

HDFC Flexi Cap Fund -Direct Plan - Growth Option

Parag Parikh Flexi Cap Direct Growth

SBI ELSS Tax Saver Fund Direct Growth

HDFC Focused Fund -Direct Plan - Growth Option

HDFC ELSS TaxSaver -Direct Plan - Growth Option

Cipla to acquire 100% of Inzpera Healthsciences for Rs 110.65 crore, enhancing its consumer healthcare portfolio.

Cipla Ltd’s net profit jumped 3.73% since last year same period to ₹1,351.17Cr in the Q2 2025-2026. On a quarterly growth basis, Cipla Ltd has generated 4.13% jump in its net profits since last 3-months.

Name	Value	Action
MACD level (12,26)	0.34	Bullish
CCI (20)	482.87	Bearish
RSI (14)	56.97	Neutral
Momentum (10)	1.7	Bullish
ADI (14)	21.78	Neutral
Ultimate Oscillator (7,14,28)	28.96	Bearish

Name	Value	Action
SMA (20)	1503.56	Bullish
EMA (20)	1503.61	Bullish
VWMA (20)	1503.74	Bullish
SMA (50)	1502.88	Bullish
EMA (50)	1503.17	Bullish
SMA (200)	1502.82	Bullish
EMA (200)	1503.06	Bullish
KAMA (200)	1502.66	Bullish
DEMA (200)	1502.41	Bullish

Cipla Ltd (CIPLA)

Summary

Overall

Oscillators

Moving Averages